Ensysce Biosciences, Inc. (ENSCW) Stock Analysis
DELISTED 2026
What happened to Ensysce Biosciences, Inc. (ENSCW) stock?
Ensysce Biosciences, Inc. (ENSCW) no longer trades on public markets. It was delisted in June 2026. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ensysce Biosciences, Inc. (ENSCW) trades at $0.0011. Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing novel pain relief and abuse-deterrent opioid products. Their technology platforms aim to address opioid misuse, abuse, and overdose. Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for ENSCW: ENSCW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ENSCW against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Ensysce Biosciences, Inc. (ENSCW) Healthcare & Pipeline Overview
Ensysce Biosciences, Inc. develops prescription drugs for severe pain relief and to prevent opioid misuse, abuse, and overdose. Utilizing Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms, the company targets safer pain management solutions within the biotechnology sector.
What Is the Investment Thesis for ENSCW?
Ensysce Biosciences presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's innovative TAAP and MPAR platforms address a critical unmet need for safer opioid pain management solutions. The success of PF614 and PF614-MPAR in clinical trials and subsequent regulatory approval are key value drivers. The company's ability to secure partnerships and funding to advance its pipeline is crucial. However, the company's limited financial resources, negative profit margin of -244.5%, and the inherent risks associated with pharmaceutical development pose significant challenges. The outcome of clinical trials for PF614 and PF614-MPAR, expected to yield results over the next 12-24 months, will be pivotal in determining the company's future prospects. Achieving commercial success in a competitive market dominated by established pharmaceutical companies is also a key factor.
Based on FMP financials and quantitative analysis
ENSCW Key Highlights
Ensysce Biosciences is a clinical-stage pharmaceutical company focused on developing abuse-deterrent opioid products.
- The company's Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms are designed to reduce opioid misuse and overdose.
- Lead product candidate PF614 is a TAAP prodrug of oxycodone for the treatment of acute and chronic pain.
- The company is also developing PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection.
- Ensysce Biosciences has a market capitalization of $0.00B and a negative profit margin of -244.5%.
Who Are ENSCW's Competitors?
ENSCW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ENZN Enzon Pharmaceuticals, Inc. | $4.71 | +1.29% | $31.1M | 42 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ENSCW's Key Strengths?
Innovative technology platforms (TAAP and MPAR).
- Strong patent portfolio.
- Focus on addressing the opioid crisis.
- Experienced management team.
What Are ENSCW's Weaknesses?
Limited financial resources.
- Reliance on external funding.
- Early-stage clinical development.
- Small number of employees.
What Could Drive ENSCW Stock Higher?
Clinical trial results for PF614 in Q3 2026 could drive positive momentum if successful.
- Potential partnerships with pharmaceutical companies in H2 2026 could provide funding and validation.
- Regulatory approvals for PF614-MPAR could lead to commercialization.
- Development of novel drug delivery systems could improve product efficacy and safety.
- Expansion into new therapeutic areas could diversify the product portfolio.
What Are the Key Risks for ENSCW?
Financial-distress signal — its Altman Z-Score of -9.99 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for PF614 or PF614-MPAR could negatively impact the stock price.
- Competition from established pharmaceutical companies could limit market share.
- Regulatory hurdles could delay or prevent product approvals.
- Limited financial resources could hinder the company's ability to fund its operations.
- Reliance on external funding could dilute existing shareholders.
What Are the Growth Opportunities for ENSCW?
- Expansion of the TAAP and MPAR platforms into new therapeutic areas: Ensysce can leverage its proprietary technology to develop abuse-deterrent formulations for other drugs with a high potential for misuse, such as stimulants and benzodiazepines. The market for abuse-deterrent formulations is expanding, driven by regulatory initiatives and growing awareness of the opioid crisis. This expansion could open up new revenue streams and diversify the company's product portfolio. The timeline for this growth opportunity is estimated at 3-5 years, pending successful clinical trials and regulatory approvals.
- Partnerships with pharmaceutical companies: Ensysce can collaborate with larger pharmaceutical companies to co-develop and commercialize its products. These partnerships can provide access to funding, expertise, and distribution networks. The pharmaceutical industry is increasingly seeking innovative solutions to address the opioid crisis, making Ensysce an attractive partner. This could accelerate the development and commercialization of Ensysce's products, leading to faster revenue growth. The timeline for securing partnerships is ongoing.
- Development of novel drug delivery systems: Ensysce can invest in the development of novel drug delivery systems to improve the efficacy and safety of its products. This could include the development of long-acting injectable formulations or transdermal patches. The market for advanced drug delivery systems is growing rapidly, driven by the increasing demand for more convenient and effective treatments. This could provide Ensysce with a competitive advantage and differentiate its products from those of its competitors. The timeline for this growth opportunity is estimated at 5-7 years.
- Geographic expansion: Ensysce can expand its operations into new geographic markets, such as Europe and Asia. These markets offer significant growth potential, driven by the increasing prevalence of chronic pain and the growing awareness of the opioid crisis. However, geographic expansion requires significant investment in regulatory affairs, marketing, and distribution. The timeline for this growth opportunity is estimated at 3-5 years.
- Acquisition of complementary technologies or companies: Ensysce can acquire complementary technologies or companies to expand its product portfolio and strengthen its competitive position. This could include the acquisition of companies with expertise in pain management, addiction treatment, or drug delivery. Acquisitions can provide access to new technologies, products, and markets, accelerating the company's growth. The timeline for this growth opportunity is ongoing.
What Are ENSCW's Competitive Advantages?
- Proprietary technology platforms (TAAP and MPAR) that create barriers to entry.
- Patent protection for its drug candidates and formulations.
- First-mover advantage in developing abuse-deterrent opioid products.
- Expertise in drug delivery and formulation.
What Does ENSCW Do?
Ensysce Biosciences, Inc., founded to address the critical need for safer pain management options, is a clinical-stage pharmaceutical company headquartered in La Jolla, California. The company is dedicated to developing innovative prescription drugs designed to provide effective pain relief while minimizing the risks associated with opioid misuse, abuse, and overdose. Ensysce's core technology revolves around two primary platforms: Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR). The TAAP technology creates abuse-resistant opioid prodrugs that require activation by trypsin, an enzyme found in the small intestine, reducing the potential for abuse through alternative routes of administration. The MPAR platform is designed to prevent overdose by combining an opioid prodrug with a trypsin inhibitor, providing an additional layer of protection against excessive oral ingestion. Ensysce's lead product candidate, PF614, is a TAAP prodrug of oxycodone intended for the treatment of acute and chronic pain. The company is also developing PF614-MPAR, a combination product of PF614 and nafamostat, designed to offer overdose protection. In addition to pain management, Ensysce is exploring the use of nafamostat in oral and inhalation drug products for coronaviral infections and other pulmonary diseases, such as cystic fibrosis. Furthermore, the company is developing PF8001 and PF8026, extended and immediate-release prodrugs of amphetamine for ADHD medication abuse. Ensysce's focus on innovative drug delivery and abuse-deterrent technologies positions it as a player in the evolving landscape of pain management and addiction prevention.
What Products and Services Does ENSCW Offer?
- Develops prescription drugs for severe pain relief.
- Focuses on preventing opioid misuse, abuse, and overdose.
- Utilizes Trypsin Activated Abuse Protection (TAAP) platform.
- Employs Multi-Pill Abuse Resistance (MPAR) platform.
- Develops PF614, a TAAP prodrug candidate of oxycodone.
- Develops PF614-MPAR for overdose protection.
- Explores nafamostat for coronaviral infections and pulmonary diseases.
- Develops PF8001 and PF8026 for ADHD medication abuse.
How Does ENSCW Make Money?
- Develops and patents novel pharmaceutical products.
- Outlicenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties.
- Focuses on research and development to create innovative drug formulations.
What Industry Does ENSCW Operate In?
Ensysce Biosciences operates within the biotechnology industry, specifically targeting the pain management and addiction treatment markets. The opioid crisis has created a significant demand for safer and more abuse-deterrent pain medications. The industry is characterized by intense competition, stringent regulatory requirements, and high R&D costs. Companies like Ensysce are striving to develop innovative solutions to address the challenges of opioid abuse and overdose.
Who Are ENSCW's Key Customers?
- Pharmaceutical companies seeking to license or acquire novel drug candidates.
- Patients suffering from severe pain who require effective and safe pain relief.
- Healthcare providers who prescribe pain medications.
- Government agencies and organizations focused on addressing the opioid crisis.
Company Profile
Ensysce Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in La Jolla, US. The company is led by CEO D. Lynn Kirkpatrick. ENSCW has traded publicly since 2021.
Financial Health
Ensysce Biosciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.99 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Ensysce Biosciences, Inc. revenue of about $6.8M for fiscal 2026, with EPS near $-1.98.
ENSCW Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that those closest to the business believe in its potential.
- Community sentiment has shifted positively, with increased discussions around upcoming product developments and their implications for market entry.
- The focus on innovative drug delivery systems aligns with growing trends in personalized medicine, attracting interest from investors looking for cutting-edge solutions.
- Positive media coverage around recent clinical trials has generated buzz, enhancing the company's visibility and perceived credibility in the biotech space.
Bear Case
- Concerns about the long timeline for regulatory approvals may dampen enthusiasm, as investors often seek quicker returns in the biotech sector.
- Market perception remains cautious due to the competitive landscape in drug development, with many players vying for similar innovations.
- Recent volatility in social sentiment reflects mixed opinions, with some community members expressing skepticism about the company's ability to deliver on its promises.
- Insider selling activity in the past raises questions about confidence levels among some executives, potentially impacting investor trust.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
ENSCW Latest News
No recent news available for ENSCW.
Leadership: D. Lynn Kirkpatrick
CEO
D. Lynn Kirkpatrick serves as the CEO of Ensysce Biosciences, Inc. Her background includes extensive experience in the pharmaceutical industry, with a focus on drug development and commercialization. She has held leadership positions in various biotechnology companies and has a proven track record of bringing innovative products to market. Her expertise spans areas such as clinical research, regulatory affairs, and business development. She is managing a team of 7 employees.
Track Record: Under D. Lynn Kirkpatrick's leadership, Ensysce Biosciences has focused on advancing its TAAP and MPAR platforms and progressing its lead product candidates through clinical trials. Key milestones include the development of PF614 and PF614-MPAR, as well as the exploration of nafamostat for coronaviral infections. Her strategic decisions have been instrumental in securing funding and partnerships to support the company's growth.
ENSCW OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Ensysce Biosciences may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies on this tier may have limited information available to investors, and the trading of their securities may be subject to greater risks and volatility compared to companies listed on national exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier requires a higher degree of due diligence and risk tolerance.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Higher price volatility.
- Lower trading volume.
- Potential for fraud or manipulation.
- Less regulatory oversight.
- Verify the company's financial statements.
- Research the management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's SEC filings (if any).
- Consult with a financial advisor.
- Understand the risks associated with OTC investing.
- Check for any legal or regulatory issues.
- Focus on addressing the opioid crisis.
- Innovative technology platforms (TAAP and MPAR).
- Strong patent portfolio.
- Experienced management team.
Common Questions About ENSCW (Healthcare)
What happened to Ensysce Biosciences, Inc. (ENSCW) stock?
Ensysce Biosciences, Inc. (ENSCW) no longer trades on public markets. It was delisted in June 2026. The figures below are historical and are not a current quote.
Can I still buy ENSCW shares?
No. ENSCW stopped trading on public markets in June 2026, so the shares are not available through a broker. Anything you see quoted for ENSCW elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ENSCW stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Ensysce Biosciences, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Ensysce Biosciences, Inc. do?
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to developing novel pain relief and abuse-deterrent opioid products. The company's core technology revolves around two primary platforms: Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR).
What are the main risks for ENSCW?
Ensysce Biosciences faces several key risks inherent to the biotechnology industry and its specific business model. Clinical trial failures for its lead product candidates, PF614 and PF614-MPAR, pose a significant threat. Competition from established pharmaceutical companies with greater resources and market presence could limit its market share.
What are the key growth opportunities for ENSCW in healthcare?
Ensysce Biosciences has several potential growth opportunities within the healthcare sector. Expansion of the TAAP and MPAR platforms into new therapeutic areas beyond pain management, such as ADHD or other CNS disorders, could broaden its product pipeline. Securing partnerships with larger pharmaceutical companies for co-development and commercialization of its products could provide access to funding, expertise, and distribution networks.
How does Ensysce Biosciences, Inc. manage patent expiration risks?
As a clinical-stage pharmaceutical company, Ensysce Biosciences faces the risk of patent expirations on its key technologies and drug candidates. To mitigate this risk, Ensysce likely employs several strategies. This includes actively seeking new patent protection for novel formulations, drug delivery systems, and therapeutic uses of its existing compounds.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending for ENSCW stock.